AUS
NZ
UK
CA
USA
IND
On 15th April 2020, the Australian markets closed in red and the benchmark index S&P/ASX200 settled at 5466.7 with a fall of 21.4 points. S&P/ASX 200 Energy (Sector) went down by 214.1 points to 6,801.4. S&P/ASX 200 Health Care (Sector) closed at 44,597.0, reflecting a decline of 0.28%. At the close of same trading session, All Ordinaries fell by 19.2 points and ended at 5523.3.
Let us now look at the performance of some individual companies, which ended in green despite the fall in market. Ingenia Communities Group (ASX: INA) rose by 8.824% to $3.330 per share. Mayne Pharma Group Limited (ASX: MYX) closed at $0.345, reflecting a rise of 7.812%. EML Payments Limited (ASX: EML) soared 7.197% to $2.830 per share.
S&P/NZX50 settled at 10,410 with a rise of 2.47% at the end of trading session on 15th April 2020. Geo Limited (NZX: GEO) gained 33.33% and ended at NZ$0.056 per share. Vista Group International Ltd (NZX: VGL) was up by 20.69% to NZ$1.400. When it comes to losers, SeaDragon Limited (NZX: SEA) plunged 16.00% to NZ$0.105 per share.
Recently, we have written an article on Perpetual Resources Limited (ASX:PEC) covering some important information. Readers can click here to view information.
Ingenia Communities Group Ended in Green on 15th April 2020
Ingenia Communities Group (ASX:INA) recently announced that Robert John Morrison has made a change to holdings in the company by acquiring 30,000 fully paid stapled securities at the consideration of $3.25 per stapled security on 7th April 2020. For 1H FY20, the company reported a rise of 52% in underlying profit, which amounted to $26.5 million. For the same period, its revenue and EBIT stood at $116.9 million and $32.2 million, reflecting rise of 25% and 40%, respectively. It attained 140 new home settlements, which reflects an increase of 22% over 1H FY19, with these settlements adding around $1.2 million in annual rental income throughout the Group. The company is in a strong position, with a sector leading development pipeline and opportunities to acquire existing communities as well as sites for future development despite the increasing competition.
Mayne Pharma Group Limited Rose by 7.812% on Australian Stock Exchange.
Mayne Pharma Group Limited (ASX:MYX) has notified the market about the disappointing results for first half of financial year 2020. These were impacted by competition experienced on its key generic products. It posted revenue and EBITDA amounting to $227.2 million and $34.6 million on a reported basis, reflecting a decline of 17% and 47%, respectively. With respect to Generic Products Division, the company reported sales amounting to $124.5 million, indicating a decline of 29% over pcp. This was impacted by intense competition on the key products and stock writedowns of $5.5 million because of discontinuation of unprofitable generic products as well as abnormal gross-to-net charges of $5.5 million from returns and government fees. In another update, the company announced that it has appointed Nick Freeman as Chief Financial Officer (CFO) and Company Secretary.
